Q2053 Brexucabtagene car pos t
Also known as: Tecartus, brexucabtagene autoleucel, CAR-T
Brexucabtagene autoleucel CAR-T cell immunotherapy for CD19-positive B-cell malignancies.
In Plain Language
cancer cell fighter; engineered cell therapy
Clinical Context
Used for relapsed/refractory mantle cell lymphoma. CAR-T cells target CD19+ B-cells. Requires hospitalization and monitoring for cytokine release syndrome.
RVU Information
CPT Q2053 does not have a physician work RVU assigned by CMS. Reimbursement for this code is determined by payer-specific fee schedules.
Billing & Documentation
Q-codes are temporary HCPCS codes used when no permanent code exists. Coverage and reimbursement vary by payer and region. Document the clinical indication and medical necessity. These codes may be replaced by permanent codes in future HCPCS updates.
Specialties
Frequently Asked Questions
What is CPT code Q2053?
CPT Q2053 (Brexucabtagene car pos t) is a Q Codes code. Brexucabtagene autoleucel CAR-T cell immunotherapy for CD19-positive B-cell malignancies.
Is Q2053 covered by insurance?
Q2053 is a temporary HCPCS code. Coverage varies by payer and may change when permanent codes are assigned. Used for relapsed/refractory mantle cell lymphoma. CAR-T cells target CD19+ B-cells. Requires hospitalization and monitoring for cytokine release syndrome.
When is CPT Q2053 used?
Used for relapsed/refractory mantle cell lymphoma. CAR-T cells target CD19+ B-cells. Requires hospitalization and monitoring for cytokine release syndrome.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against national data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.